



REVIEW ARTICLE

The molecular genetics of PI3K/PTEN/AKT/mTOR pathway in the malformations of cortical development

Qing Ma ^{a,1}, Guang Chen ^{b,1}, Ying Li ^{a,c}, Zhenming Guo ^d,
Xue Zhang ^{a,*}

^a NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, Heilongjiang 150000, China

^b Department of Urology, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang 150000, China

^c Department of Child and Adolescent Health, School of Public Health, Harbin Medical University, Harbin, Heilongjiang 150000, China

^d Institute for Regenerative Medicine, Shanghai East Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai 200120, China

Received 7 December 2022; received in revised form 7 April 2023; accepted 30 April 2023

Available online 16 July 2023

KEYWORDS

Epilepsy;
Gene mutation;
Genetics;
Malformations of
cortical
development;
PI3K/PTEN/AKT/
mTOR pathway

Abstract Malformations of cortical development (MCD) are a group of developmental disorders characterized by abnormal cortical structures caused by genetic or harmful environmental factors. Many kinds of MCD are caused by genetic variation. MCD is the common cause of intellectual disability and intractable epilepsy. With rapid advances in imaging and sequencing technologies, the diagnostic rate of MCD has been increasing, and many potential genes causing MCD have been successively identified. However, the high genetic heterogeneity of MCD makes it challenging to understand the molecular pathogenesis of MCD and to identify effective targeted drugs. Thus, in this review, we outline important events of cortical development. Then we illustrate the progress of molecular genetic studies about MCD focusing on the PI3K/PTEN/AKT/mTOR pathway. Finally, we briefly discuss the diagnostic methods, disease models, and therapeutic strategies for MCD. The information will facilitate further research on MCD. Understanding the role of the PI3K/PTEN/AKT/mTOR pathway in MCD could lead to a novel strategy for treating MCD-related diseases.

© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: xuezhang@hrbmu.edu.cn (X. Zhang).

Peer review under responsibility of Chongqing Medical University.

¹ These authors contributed equally to this work.

Introduction

The cerebral cortex is responsible for receiving and processing information and issuing instructions and is undertaking higher functions such as sensory, cognition, controlling emotions, and generating consciousness, which is extremely critical to the normal functioning of the organism.¹ Cortical development is a highly sophisticated and well-organized process, including neural stem cell proliferation and differentiation, neuron migration and maturation, and the production of glial cells. Abnormalities can occur in any part of these processes, which may lead to the malformations of cortical development (MCD). MCD is the principal cause of intellectual disability, autism, epilepsy, and cerebral palsy.² Further, the treatment for MCD is not satisfactory, and the prognosis is dire. Understanding the mechanism of MCD is fundamentally essential and may lead to novel approaches to curing MCD in clinical settings.

Over the last decade, increasing evidence has shown that the dysregulation of the PI3K/PTEN/AKT/mTOR pathway is one of the critical causes of MCD.^{3–7} By regulating protein synthesis, the PI3K/PTEN/AKT/mTOR signaling pathway can modulate cell growth, proliferation, differentiation, and apoptosis.⁸ Furthermore, in the central nervous system, it can modulate cortical developmental processes by regulating the proliferation of neural stem cells, neuron development, gliogenesis, synaptic plasticity, and the assembly and maintenance of circuits.^{9,10} Recently, evidence has shown that genetic events can cause the dysregulation of the pathway and further lead to impairment of cortex development. Thus, revealing the molecular genetic events in the PI3K/PTEN/AKT/mTOR pathway may contribute to diagnosing and treating MCD. Many drugs that target specific genes of this pathway have been developed, such as the mTOR inhibitor rapamycin, which can effectively inhibit neuronal overgrowth and epileptic phenotype in mice with MCD.^{11–18} This review mainly discusses the molecular genetics and pathogenic mechanisms of MCD by focusing on the PI3K/PTEN/AKT/mTOR pathway and briefly introduces related disease models and targeted therapeutic advances.

Developmental processes and diseases of the cerebral cortex

The development of the central nervous system originates from the neural tube composed of monolayer pseudostriated neuroepithelial cells (NEs). With the closure of the neural tube, three brain vesicles (prosencephalon, mesencephalon, and rhombencephalon) take shape in the anterior part of the neural tube, and the cephalic end of the prosencephalon expands to the sides to form the left and right telencephalon. The NEs in the telencephalic wall proliferate, differentiate, and migrate outward to evolve into the cerebral cortex. We summarize the key time points and events in cerebral cortex development (Fig. 1).

Neural stem cell pool expansion

During postconceptional week 4 (pcw4) in humans or embryonic day 9 (E9) to E10 in mice, cerebral cortex development initiates. NEs are attached to the ventricular

surface at the apex and the leptomeningeal surface at the base. The area where their cell bodies are positioned is called the ventricular zone (VZ), the most inferior part of the cortex. NEs increase the number of neural stem cells and expand the VZ by symmetrical proliferative division.^{19,20} Since pcw7 (E10), the expression of the Hes family and Fgf10 induces the transformation of NEs to radial glial cells (RGCs). These molecules both reserve some epithelial properties and express glial cell markers, such as brain-lipid-binding protein, glutamate-aspartate transporter, and glial fibrillary acidic protein.^{20–22} RGCs also increase the number of neural stem cells by symmetrical proliferative divisions as NEs. After neurogenesis, the expansion of the VZ also continues to rely on the division of RGCs. By E12, most NEs convert to RGCs, which have become the predominant neural stem cells.²³

Neurogenesis

At pcw7–8 (E10.5), the first neurons, mainly Cajal-Retzius cells,^{24,25} are generated by asymmetric division of RGCs and secrete reelin to guide neuron migration and promote neuron differentiation. Cajal-Retzius cells migrate radially between the VZ and the leptomeninges, constituting the preplate (PP).^{20,26,27} At pcw9–10 (E11.5), cortical projection neurons begin to be generated and migrate to the PP to form the cortical plate (CP), which divides the PP into two regions, the marginal zone in the superficial layer and the subplate (SP) in the deep layer.^{24,28} The marginal zone is mainly occupied by Cajal-Retzius cells, also known as layer I. At approximately E13, RGCs proliferate continuously and accumulate in the basal side of VZ, deriving another proliferation zone, the subventricular zone (SVZ). Since primates have more neural progenitors, SVZ can be subdivided into inner SVZ and outer SVZ.²³ While the stem cell pool expands, individual RGC divide by asymmetric self-renewal to produce an intermediate progenitor (IP) and a neuron, termed direct neurogenesis. IPs are mainly located in the SVZ and form the intermediate zone by massive accumulation. IPs are essential for producing numerous neurons during cortical development, and neurons can be created by the symmetric consumptive division of IPs, namely indirect neurogenesis.^{23,28,29}

Neuronal migration and cortical lamination

Neurons migrate to the CP layer through four stages. In the first stage, the neurons migrate radially to the SVZ/intermediate zone after arising from the VZ or SVZ. In the second stage, the neurons stay in the SVZ/intermediate zone for up to 24 h and exist in a multipolar pattern. Since the neurons have not yet established the tight junction with the nerve fibers of RGCs at this stage, there are lateral movements. In the third stage, the neuronal somas move backward toward the ventricle or one of the dendrites of neurons extends toward the ventricle. A portion of the neurons, which can escape this stage, directly proceed to the fourth stage: the neurons invert the multipolar state, extending axons that directly attach to the leptomeninges and migrating to the particular position of the CP with the appearance of bipolar neurons.³⁰ At pcw8–24 (E12–E16.5),




Figure 1 Schematic overview of cortical development in the embryonic brain and MCD types. During the early stages of cortical development, neural stem cells undergo symmetrical proliferative division to expand the VZ pool, producing neurons by direct or indirect neurogenesis. The immature neurons migrate to specific cortical layers in the “inside-out” pattern. Subsequently, neurons mature, glial cells are generated, and the cerebral cortex is organized and connected. The abnormal cortical development process can lead to MCD, whose types are illustrated in the corresponding box. COB, cobblestone malformation; CP, cortical plate; FCD, focal cortical dysplasia; IZ, intermediate zone; MCD, malformations of cortical development; MEG, megalencephaly; MIC, microcephaly; MZ, marginal zone; PMG, polymicrogyria; PP, preplate; PVNH, paraventricular nodular heterotopia; SP, subplate; SUBH, subcortical heterotopia; SVZ, subventricular zone; VZ, ventricular zone.

following the “inside-out” developmental pattern, the CP layer emerges, which consists of six layers of neuronal cells arranged in an orderly manner.^{24,31} Neurons produced earlier migrate through the basal neurites of the RGCs to the deeper layer of CP, and neurons subsequently produced can cross over the neuronal layers constituted by neurons previously produced to reach the location closer to the meninges and form new neuronal layers. The layer VI neurons begin to be produced at E12.5, the layer V at E13.5, and then until E16.5 when the last batch of neurons are produced to form layer II of the cortex.^{32,33} Once neurons reach their final position within the cortex, dendrites and axons grow, and synapses develop. Neurons located in the marginal zone and SP are the first to shape synapses and mature in morphology, contributing to the migration of CP neurons, the development of synapses, and the formation of afferent and efferent nerves.³⁴

Gliogenesis

After pcw24 (E17), the proliferation of RGCs and cortical neurogenesis gradually decrease, while RGCs transform into glial cell progenitors, giving rise to astrocytes, oligodendrocytes, and ependymal. Oligodendrocytes (OLs) generate myelin through the spiral wrapping of their plasma membranes around axons. The myelin can accelerate neurotransmission, provide trophic support to axons, and refine neural circuits.^{35,36} The brain continues to undergo dramatic changes even after birth, with neuronal morphology maturation, axonal myelination, synaptogenesis, and neural network formation and remodeling throughout the early life span.^{37,38}

Malformations of cortical development

The development of the cerebral cortex is intricate and sophisticated, depending on three basic processes: neuron progenitor proliferation, neuron migration, and cerebral cortex organization. Disruption of any of these steps by inherited factors like mutations of related genes or harmful external environmental factors, including alcohol, radiation, and viral or bacterial infections can lead to MCD. Based on the implicated cortical developmental processes, MCD can be divided into three categories³⁹: (i) MCD due to abnormal neuron and glial cell proliferation and apoptosis, such as microcephaly (MIC) and megalencephaly (MEG). MIC is defined as a head circumference measurement smaller than a certain value for babies of the same age and sex, and vice versa. MIC can present with a normal or simplified gyral pattern or with more complex brain abnormalities, which are often associated with epilepsy, autism, and other birth defects. MEG may associate with underlying neurodevelopmental or generalized overgrowth disorders.⁴⁰ (ii) MCD due to impaired neuron migration, such as paraventricular nodular heterotopia (PVNH), lissencephaly spectrum, subcortical heterotopia, and cobblestone malformation (COB). Neuronal heterotopia means groups of neurons in an abnormal location, lissencephaly refers to the abnormal gyral pattern, and COB exhibits irregular and pebbled-like lesions in the cortical surface resulting from the over-migration from the CP into the leptomeninges.² (iii) MCD due to abnormal post-migration cortical organization and connection, such as polymicrogyria (PMG), dysgyria, and focal cortical dysplasia (FCD). PMG is characterized by excessively small

cerebral gyri with an irregular, pebbled cortical surface and a stippled grey-white matter boundary, which is difficult to be distinguished from COB.⁴¹ FCD is characterized by deranged neurons in white matter, dyslamination, and abnormal balloon cells, leading to a higher risk of seizures and possible intellectual impairment.⁴² According to the International League Against Epilepsy (ILAE), FCD I has abnormal lamination, FCD II is associated with aberrant cytology, and FCD III occurs alongside another lesion, including hippocampal sclerosis or tumors.^{39,43} It is worth noting that FCD I and FCD III belong to the class II MCD. Hemimegalencephaly (HME), FCD II, and tuberous sclerosis complex (TSC), which share similar genetic etiologies and histopathological features, are all classified as class III MCD.^{44–46} HME is usually severe because of the larger lesions.¹² However, TSC and FCD are not the same disorder. TSC shows unique clinical manifestations, including hamartomas, cortical tubers, impaired myelination of the lesional white matter, neuronal migration lines (NML), and tumor-like lesions, such as subependymal nodules (SEN) and subependymal giant cell astrocytoma (SEGA).^{47,48} With the development of molecular genetics, the classification of MCD based on gene mutations and signaling pathways can complement and extend histopathological classification.³⁹

PI3K/PTEN/AKT/mTOR pathway

Normal physiological PI3K/PTEN/AKT/mTOR pathway

The PI3K/PTEN/AKT/mTOR pathway plays key roles in cortical development, participating in several processes, including neuron proliferation, axon and dendrite growth, dendritic branching, and synapse formation. This pathway also facilitates the establishment of polarity in immature neurons and the maintenance of polarity in mature neurons (Fig. 2).^{49–52} Phosphatidylinositol-3-kinase (PI3K) is the necessary component for activating this pathway. The main downstream target of PI3K is AKT serine/threonine kinase (AKT), which is vitally important among a wide range of biological processes such as cell growth, survival, and metabolism.⁵³ AKT, also known as protein kinase B, which can be phosphorylated and activated by various cellular components, could directly or indirectly regulate the mechanistic target of rapamycin kinase (mTOR) which is the downstream master effector molecule.⁵⁴ AKT also directly acts on the downstream GSK-3 β (glycogen synthase kinase-3 β)/CCND2 signaling pathway to regulate protein synthesis.⁵⁵ mTOR functions by forming mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) with related proteins. mTORC1 mainly regulates two signaling pathways, ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E (eIF4E)-binding proteins (4E-BPs) pathway, which engages in the assembly of translation initiation complex and protein synthesis^{56,57}; mTORC2 can regulate the pathway activation state by phosphorylating AKT.⁵⁸ In addition, the PI3K/PTEN/AKT/mTOR pathway also maintains homeostasis by the activation of negative regulators. The phosphatase and tensin homolog (PTEN) act on

PIP3 to dephosphorylate it to PIP2, reducing activated AKT levels.⁵⁹ The TSC complex subunit 1/2 (TSC1/2) inhibits mTOR activation mediated by RHEB (Ras homolog mTORC1 binding). mTORC1 indirectly inhibits AKT activity by antagonizing mTORC2, thereby inhibiting the activity of the PI3K/AKT/mTOR pathway.⁵⁸


PI3K/PTEN/AKT/mTOR pathway in abnormal cortical developmental states

PI3K

PI3K, a member of the lipid kinase family, can be classified according to substrate preference and sequence homology. Class IA PI3K is predominantly expressed in the brain and is the heterodimer consisting of regulatory subunits encoded by *PIK3R1*, *PIK3R2*, and *PIK3R3* and catalytic subunits encoded by *PIK3CA*, *PIK3CB*, and *PIK3CD*. In response to extracellular signals, such as fibroblast growth factor, the class IA PI3K regulatory subunit is phosphorylated via receptor tyrosine kinases (RTKs) to activate p110, encoding by *PIK3CA*, thereby activating the PI3K/AKT pathway.^{60,61} Activated PI3K is recruited to the cell membrane and preferentially acts on the substrate phosphatidylinositol-4,5-bisphosphate (PIP2) to generate the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3).⁶² PIP3 interacts directly with the AKT PH domain, aggregating inactivated AKT in the cell membrane and causing the conformational change that makes it susceptible to be phosphorylated at Thr308 by phosphoinositide-dependent kinase 1 (PDK1).⁶³ Additionally, RAB39B can interact with PI3K components. Deficiency of RAB39B can induce abnormalities of the PI3K/AKT/mTOR pathway in the mouse cortex and cerebral organoid.⁶⁴

PIK3CA and *PIK3R2* encode the catalytic subunit p110 α and the regulatory subunit p85 β of PI3K, respectively. *PIK3CA* mutations are distributed throughout the entire coding sequence,⁶⁵ and the hotspot mutation regions may be helical and kinase domains.⁶⁶ Mutations at different domains may induce PI3K hyperactivation by different molecular mechanisms. Mutations in the C2 domain may alter charge or conformation, enhancing recruitment of the mutant-p110 α to cell membranes; mutations in the helical domain may affect the interaction with other proteins; mutations in the kinase domain, near the hinge of the activation loop, may alter the position of the activation loop.⁶⁷ Several *PIK3R2* mutations can disrupt the inactive conformation of the PI3K dimer and hyperactivate catalytic subunit,^{68,69} like mutations in the conserved residues located at the binding site of p110 α and p85 β and the SH2 domain, can cause sustained activation of the catalytic subunit by affecting the binding of the two subunits.^{70,71} *PIK3CA* or *PIK3R2* mutations result in increased PI3K activity. PI3K with enhanced activity aggregates towards the cell membrane, more PIP3 is generated and induces PDK1 to locate at the cell membrane, and the phosphorylation of AKT increases, resulting in the entire pathway in the hyperactivated state.^{65,67–69} The above reasons lead to abnormalities in the downstream signaling pathways, affecting the growth and development of neurons and synaptic plasticity, resulting in neuronal hypertrophy, as well as abnormalities in the morphology, location, and

A



B




Figure 2 PI3K-PTEN-AKT-mTOR pathway and MCD. (A) The PI3K-AKT-mTOR pathway in the normal state. The activated effects of genes on the downstream signaling components are represented by canal blue arrows, and the inhibitory effects are represented by orange arrows. (B) The PI3K-AKT-mTOR pathway in the abnormal pathological state. The genes with GOF mutations leading to MCD are colored in light pink, and the genes with LOF mutations leading to MCD are colored in orange. The specific MCD diseases caused by gene mutations are organized in the corresponding boxes. FCD, focal cortical dysplasia; HME, hemimegalencephaly; MEG, megalencephaly; MIC, microcephaly; PMG, polymicrogyria.

number of synapses and neurites.^{72,73} Megalencephaly-capillary malformation syndrome (MCAP), HME, and other disorders associated with cellular overgrowth due to mutations in *PIK3CA* are now generically referred to by the term "PIK3CA-related overgrowth spectrum".⁷⁴

PIK3CA mutations cause diseases such as MCAP, HME, and MEG. The most common mutation is the somatic heterozygous mutation.^{75,76} Swarr et al reported that MCAP fetuses carrying the heterozygous mutation (p.R115P) in *PIK3CA* developed pleural effusions and fetal hydrops.

Thus, MCAP syndrome should be considered when a fetus suffered non-immune hydrops.⁷⁷ *PIK3CA* mutant mice with MEG and hypoglycemia phenotypes were discovered in 2015,⁷⁸ and then four MCAP children with *PIK3CA* mutation showed hypoglycemia symptoms in 2018.^{79,80} Subsequently, nine MCAP children with *PIK3CA* mutation exhibited growth hormone deficiency. Therefore, the researchers recommend assessing MCAP children's glucose levels and performing early endocrine surveillance for them.^{79,80} Moreover, an MCAP girl with a recurrent *PIK3CA* somatic mutation (p.Glu453Lys) had elevated glycated hemoglobin levels and pancreatic steatosis. This case indicates that pancreatic screening is critical for patients with *PIK3CA*-related disease.⁸¹

Both germline and somatic mutations of *PIK3R2* can cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH) and bilateral perisylvian polymicrogyria.^{70,71,82}

PTEN

PTEN, a lipid and protein phosphatase, dephosphorylates PIP3, thereby inhibiting the accumulation of PIP3 in cells and suppressing the PI3K/AKT pathway. Experiments *in vitro* and *in vivo* showed that deficiency of *PTEN* can increase phosphorylated AKT and S6^{83,84} and over-activate PI3K/AKT pathway, leading to cortical developmental disorders.^{84,85}

PTEN mutations cause cortical developmental disorders such as FCD and MEG. Schick et al reported a somatic missense mutation in *PTEN* in FCD patients.⁸⁶ Several *de novo* germline missense and frameshift mutations in the *PTEN* were found in patients with autism spectrum disorder (ASD), and MEG was the typical phenotype of these ASD patients.^{87–89}

PTEN haploinsufficiency mice can exhibit increased cortical neuronal cell soma volume and dendritic complexity, axons arising from cortical neurons are overgrown, and the mice develop MEG phenotype and exhibit behavioral abnormalities.^{90–92} The conditional *PTEN* knockout mice may show disrupted migration, enhanced neural stem cell proliferation and differentiation, hypertrophic neurons, and altered neuronal membrane properties.^{93,94} The mice can exhibit progressive MEG, spontaneous seizures, abnormal electroencephalography activity, and ASD-related behavioral abnormalities.^{95,96}

AKT

AKT is vital for regulating cell growth. AKT1 and AKT3 are the main forms of AKT in the cerebral cortex. AKT3 is enriched in the RGCs and acts as a key protein for cortex development.^{97,98} AKT is phosphorylated on two key residues. One residue is the prementioned Thr308 phosphorylated by PDK1. The other is Ser473 phosphorylated by mTORC2, which may further increase AKT activity. AKT occupies the central position in the pathway, transmitting the upstream signal to the downstream, and is essential for the proper activation of the entire signaling pathway.

The gain of function (GOF) mutations at the PH domain, catalytic kinase domain, and the C-terminus of AKT can lead to ongoing activation of AKT and the PI3K/PTEN/AKT/mTOR pathway, causing MCD associated with cortex overgrowth.⁹⁹

The GOF mutations of the *AKT3* are associated with a wide spectrum of brain involvement ranging from focal or segmental brain malformations (such as HME and PMG) to diffuse bilateral cortical malformations, MEG, and heterotopia.⁹⁹ *AKT3* gene dosage imbalances are involved in the control of brain growth.¹⁰⁰ For example, people with *AKT3* duplication mutations or tetraploids suffer from MEG and related syndromes (MCAP and MPPH).^{68,70,101} *AKT3* somatic GOF mutation can also lead to MCD, such as HME, resulting from *AKT3* hyperactivation.^{75,98} AKT overactivation can increase glucose utilization. Thus, MCD patients with GOF mutations of *AKT*, such as *AKT3* mutation (p.Val183Asp), may be accompanied by persistent hypoglycemic symptoms.¹⁰² Also, growth hormone deficiency and hypoglycemia occurred in the children suffering from MCD due to *AKT3* germline mutation (p.Glu40Lys).¹⁰³ Besides *AKT3*, Cowden syndrome patients with *AKT1* germline mutation and Proteus syndrome patients with somatic GOF mutation of *AKT1* also showed MEG and HME.^{67,104,105}

On the other hand, loss of function (LOF) mutations of *AKT3* can cause MIC.^{106,107} Ciaccio et al proposed the term "Mirror syndromes" characterized by MIC, assuming a mechanism contrary to the overactivation of the PI3K/PTEN/AKT/mTOR pathway.¹⁰⁸ Moreover, in contrast to the enlarged brain size in mice with *AKT3*-activated mutations (p.D219V), *AKT3* knockout mice show that brain size decreases selectively due to the reduction of neuron number and size.¹⁰⁹ However, verifying this hypothesis by identifying more MIC cases resulting from the LOF mutations of other genes in this pathway is still necessary.

When the genes that encode AKT positive or negative regulators are mutated, sustained activation of the PI3K pathway and MCD occur.¹¹⁰ Protein phosphatase 2 regulatory subunit B' delta (PPP2R5D) is the component of PP2A. Its mutants interact with AKT, leading to continuous activation of the pathway and triggering cell size increase and cell growth dysfunction,¹¹¹ which causes MEG eventually.¹¹² Alternatively, P21-activated kinase 1 (PAK1) is a positive regulator of AKT. PAK1 mutants increase AKT phosphorylation levels, leading to sustained pathway activation and causing MEG.¹¹³

In addition, GSK-3 β is a critical molecule downstream of AKT.¹¹⁴ Activated AKT directly phosphorylates GSK-3 β to make it inactive and deliver the signals against apoptosis.¹¹⁵ AKT is a crucial regulator of neural crest induction because the inhibition of GSK-3 β can stabilize its substrates (β -catenin and Snai1), which are essential for neural crest and cranial bone development.¹¹⁶ Also, GSK-3 β phosphorylates cyclin D2 (CCND2) and makes CCND2 more sensitive to the degradation mediated by ubiquitin or protease,¹¹⁷ regulating neural progenitor proliferation and differentiation.^{118,119} It seems that these factors can regulate brain shape and head size at the same time.

GSK-3 β is a critical factor for establishing neuronal polarity, and the mutations of key genes in this pathway may directly regulate axon formation by affecting GSK-3 β function.¹²⁰ For example, the mutations of *DDX3X* and *RAC1*, which are the upstream genes of AKT, can make GSK-3 β fail to stabilize β -catenin and Snai1, leading to craniofacial disorders and MCD, such as MIC, MEG, and PMG.^{121,122} The GSK-3 β is inhibited when the pathway is overactivated, causing CCND2 not to be phosphorylated and degraded,^{55,68}

the neural progenitor cell cycle decreases, and the numbers of RGCs and IPs increase, leading to MCD such as MEG.^{102,117}

The GOF mutations of *CCND2* may alter the structure of *CCND2* phosphorylation sites, whereas unphosphorylated *CCND2* resists degradation and accumulates, disrupting the normal progression of the neural progenitor cell cycle.^{55,117} Therefore, the migration of cortical neurons that GSK-3 β participates in is aberrated, leading to MCD-like MEG and polymicrogyria (PMG).⁵⁵ The hotspot mutation region of *CCND2* in MPPH patients is around its conserved residue that can be phosphorylated by GSK-3 β .⁵⁵ Interestingly, the incidence of polydactyly in MPPH patients with *CCND2* mutations is significantly higher than in MPPH patients carrying mutations of other genes in the pathway. However, the specific mechanism is unknown.^{55,123}

TSC1/2

The TSC complex, the negative regulator of the PI3K/PTEN/AKT/mTOR pathway, has three subunits: TSC1, TSC2, and Tre2-Bub2-Cdc16-1 domain family member 7 (TBC1D7).¹²⁴ TSC2 contains the GTPase-activating protein domain for a small G-protein Rheb (Ras homologue enriched in the brain), TSC1 acts as a scaffold that binds and stabilizes both TSC2 and TBC1D7^{124,125}; TBC1D7 binds to and is stabilized by TSC1, and knockdown of TBC1D7 can decrease the association of TSC1 and TSC2.¹²⁴ The TSC complex inhibits mTORC1 through its GAP (Gtpase-activating protein) activity of Rheb.¹²⁵ If the TSC complex is disrupted, Rheb will not shift from the active form (GTP-bound Rheb) to the inactive form (GDP-bound Rheb) and fail to inhibit mTORC1.^{124,126} AKT can directly phosphorylate TSC2, which destabilizes TSC2 and disrupts its interaction with TSC1.¹²⁷ Also, the phosphorylation of TSC2 by GSK-3 β may be relevant for inhibiting the TSC1/TSC2 complex.¹²⁸ In addition, serine/threonine kinase 11 combines with STE20 related adaptor- α (STRAD α) and mouse protein 25- α (MO25 α) to form a trimeric complex that can activate the TSC complex by activating protein kinase AMP-activated catalytic subunit alpha 2 (AMPK) to phosphorylate TSC2.^{129,130}

TSC1/2 somatic mutations and germline heterozygous mutations are sufficient to disrupt the structures and functions of the TSC complex,^{131,132} making it unable to inhibit mTOR activation. Similar to the mechanism of *PTEN*, *TSC* mutants disrupt the balance of the activation state of the PI3K/PTEN/AKT/mTOR pathway, leading to dysregulation of neuronal growth and ultimately causing MCD, such as FCDII, TSC, and HME.^{131,133,134}

In mice, mosaic knockout of *Tsc1* and *Tsc2* via CRISPR-Cas9 application is sufficient to cause spontaneous behavioral seizures, cytomegalic neurons, and defective neuronal migration.¹³¹ FCDII, TSC patients, and animal models showed cortical dysplasia accompanied by increased OLs progenitor proliferation, reduced myelin, and impaired white matter.^{135–139} For *TSC1/2*, a two-hit mutational mechanism is assumed to cause FCD, TSC, and HME lesions,^{105,140–143} as shown in cancer according to Knudson's two-hit model.¹⁴⁴

Besides, the LOF or GOF mutations of the genes that encode TSC complex regulators can abnormalize the activation of the pathway, causing MCD. For example, a study revealed that overexpression of dual specificity tyrosine

phosphorylation regulated kinase 1A (DYRK1A) increased phosphorylation of both TSC1 and TSC2,^{145,146} the LOF mutants of *DYRK1A* can trigger MIC.¹⁴⁷ HECT and RLD domain containing E3 ubiquitin-protein ligase family member 1 (HERC1) can interact with TSC2, and GOF mutations of *HERC1* can increase the activity of mTORC1 and persistent activation of the pathway, eliciting MEG.^{148,149}

RHEB

RHEB, as a gene in the TSC1/2 downstream, is a potent activator of mTORC1.¹⁵⁰ FKBP38 is an endogenous inhibitor of mTOR, which can bind directly to mTOR and down-regulate mTORC1 activity. GTP-bound RHEB can antagonize FKBP38 by interacting with it and preventing its association with mTOR.^{151,152}

RHEB mutations are associated with FCD, HME, and MEG. The patients also presented intellectual disability with hypotonia, epilepsy, and autism spectrum disorder.^{142,153–156} A study in Rheb knockout mice showed up to 75% reduction in mTOR signaling.¹⁵⁷ A GOF mutation of *RHEB* (p.Pro37Leu) is resistant to the inhibitory action of the TSC complex, resulting in increasing mTORC1 activity.¹⁵⁸ The RHEB mutant proteins caused neuronal migration defects and cytological abnormalities, with dysmorphic appearance and enlarged soma size, and induced aberrant axonal development *in vivo* and *in vitro*.^{154,158} The Rheb mutated mice exhibited TSC, FCD, and seizures.^{13,154,158,159} In the zebrafish model, Rheb mutant proteins significantly increased head size.¹⁵⁴ In addition, rapamycin administration released heterotopic nodules and seizures in Rheb-mutated mice,^{158,159} and an ongoing clinical trial used the mTOR inhibitor everolimus to treat patients who carried RHEB mutations.¹⁵⁶

mTOR

mTOR is a serine/threonine protein kinase that involves in cell growth and regulates cell proliferation. mTOR can phosphorylate its downstream translational control targets, 4E-BPs, and S6Ks.¹⁶⁰ 4E-BPs is composed of 4E-BP1, 4E-BP2, and 4E-BP3 in mammals, and 4E-BP2 is the most abundant isoform in the brain.^{161,162} Hypophosphorylated 4E-BPs have a high affinity for eIF4E; while hyperphosphorylated 4E-BPs can separate from eIF4E, which promotes eIF4F complex formation to initiate the translation of relevant mRNAs.^{114,163} S6Ks consist of S6K1 and S6K2 in mammals, and all phosphorylation sites are conserved between the two proteins.¹⁶⁴ Ribosome protein S6 (RPS6), the direct downstream effector of S6K, is a component of the 40S ribosome, whose phosphorylation promotes the translation of relevant mRNAs.¹⁶⁵ The mTOR pathway activation affects cell size, number, and synaptic plasticity of neurons.¹⁶⁶ Recently, mTOR was found involved in myelin formation. mTORC1 has been implicated as a key signal for myelination. It can promote the differentiation of OLs from oligodendrocyte progenitor cells and positively regulate myelin growth.³⁶ In addition, GAP activity towards rags complex 1 (GATOR1) and a four-membered protein complex (KICSTOR) can function as the inhibitor of the mTORC1 pathway in response to amino acids level.^{3,167} GATOR1, composed of DEPDC5, NPRL2, and NPRL3, can be implicated in the inhibition of Rag GTPase, which is involved in mTORC1 recruitment at the lysosome membrane, where

RHEB stimulates its kinase activity.^{54,168} KICSTOR consists of four proteins, namely, KPTN (kaptin, actin-binding protein), integrin alpha FG-GAP repeat containing 2, C12orf66, and SZT2. KICSTOR can combine with GATOR1 and recruit it to the lysosome, inhibiting mTORC1 and affecting cortical development.^{167,169}

mTOR mutations enhance its activity in various ways. Mutations at the FAT structural domain, which can limit the kinase activity of mTOR, may destabilize mTOR.¹⁷⁰ Mutations at the kinase domain may alter the mTOR helix conformation and decrease its activated threshold.^{75,171} Some other mutations may inhibit mTOR binding to Deptor, an mTOR endogenous inhibitor.¹⁷² Excessive mTOR activation directly triggers MCD such as FCD, HME, Smith-Kingsmore syndrome associated MEG, and epilepsy.^{15,75,76,173} Also, MCD cases with mutations in GATOR1 and KICSTOR genes are reported.^{3,174–180} Notably, a germline LOF mutation together with a somatic “second-hit” mutation in *DEPDC5* might be responsible for FCD’s development.¹⁸¹

In short, in the PI3K/PTEN/AKT/mTOR signaling pathway, both the GOF mutations of the genes encoded positive regulators and the LOF mutations of the genes encoded negative regulators can lead to hyperactivation of this pathway. The dysregulation of the mTOR pathway can cause abnormal RGC and OL proliferation, disturbed neuron migration, and impaired myelination. It leads to MCD with common phenotypic characteristics, such as abnormal neuronal morphology, disorganized cortical lamination, impaired myelin formation, neuronal hyperexcitability, and clinical epilepsy.^{169,182} Conveniently, MCD with the above characteristics caused by dysregulation of the pathway can be collectively referred to mTORopathies.^{45,183,184} The mutations of genes or related genes in the PI3K/PTEN/AKT/mTOR pathway caused mTORopathies are summarized in Table 1. In summary, mutations in related genes can regulate the pathway activation, affecting cortical development and leading to MCD. We can conclude that class I MCD (MEG and related syndromes (MCAP, MPPH)) is most likely related to these pathway mutations. The second related category is class III MCD, like FCDII, HME, and PMG. Some mutations also could lead to class II MCD, like heterotopia.

Diagnosis, modeling, and therapy of MCD with PI3K/PTEN/AKT/mTOR pathway-related genetic information

Recent studies have led to a further understanding of MCD. Effective diagnosis and therapy strategies based on molecular genetics and imaging have been developing. The PI3K/PTEN/AKT/mTOR pathway is critical in MCD. To investigate the pathophysiology relationship between PI3K/PTEN/AKT/mTOR pathway and MCD, it is necessary to apply multiple disease models to simulate the clinical phenotype of MCD and to explore the best disease management strategies.

Disease diagnosis

MCD should be considered for patients with intellectual disability or epilepsy. Magnetic resonance imaging (MRI) is critical for clinical diagnosis²⁰⁹ because MRI has

multidirectional and multiparametric imaging features and unique imaging advantages for abnormal cortex lesions. In addition, since many cases are detected after neurological symptoms, such as epilepsy and developmental delay, it is vital to diagnose during the fetal period. However, the detection of MCD by prenatal ultrasonography is difficult. For accuracy and sensitivity, MRI is superior to ultrasonography for diagnosing such diseases, and the application of MRI in prenatal fetal diagnosis is becoming increasingly widespread due to its high resolution.²¹⁰

MIC, paraventricular nodular heterotopia, and other MCD diseases may also be associated with structural variations, such as copy number variations, so chromosomal microarray analysis can significantly improve the diagnostic rate.^{211,212} Given the high genetic heterogeneity of MCD and the still-growing number of known causative genes and variants, targeted evaluation of MCD-associated genes in combination with high-throughput sequencing technology is recommended. If the causative variant is still not filtered, the trio exome analysis can be taken to improve the diagnosis rate after appropriate genetic counseling. Since many mutations are not detected using diagnostic MCD panels, more emphasis should give to mosaicism, especially the issue of low-allele frequencies. Analysis of resected brain tissue using deep sequencing and single-cell techniques is recommended.⁴⁴

Disease modeling

The complexity of the human brain and the limitation of obtaining lesion tissue make it challenging to study MCD. Genetically modified mouse models can be an essential strategy with strengths in neuropsychiatric and behavioral studies.^{213,214} Animal models with defects in PI3K/PTEN/AKT/mTOR pathway can partially mimic cortical neuron abnormalities, behavior abnormalities, electroencephalography abnormalities, and epilepsy. It is important for exploring the histopathological alterations, and pathophysiological mechanisms of MCD, and screening clinical intervention strategies.^{13,15,64,215–223} However, the human brain is more advanced and complex in evolution. Species differences between human and animal brain tissues make animals not fully applicable for studying human brain development and neurological disorders.²²⁴

Traditional two-dimensional monolayer cells originating from humans can eliminate species effects. For example, the primitive neural stem cells from a patient carrying *TSC2* mutations have higher proliferative activity and neurons differentiated from such cells show dysmorphic morphology and abnormal connections among cells.²²⁵ A recent study demonstrates that the OLs can make neuronal defects more apparent by generating TSC patient induced pluripotent stem cell (iPSC) derived cortical neuronal and oligodendrocyte cultures.²²⁶ It is helpful to explore neurodevelopmental diseases through cell culture, but the cells can hardly mimic the actual biological processes *in vivo*, as lacking tissue organization and complexity.

Human three-dimensional brain organoids are novel models for studying human neurodevelopmental process diseases. Cerebral organoids can recapitulate at least some aspects of human cortical development; RGCs and neurons

Table 1 PI3K-PTEN-AKT-mTOR pathway mutations in cortical developmental diseases.

Gene symbol	OMIM No.	Mutation type	Inheritance	Effect of the mutation	Phenotype	Related syndrome
<i>PIK3CA</i>	*171834	Germline, somatic	AD	GOF	MEG, PMG ¹⁸⁵ FCDII ⁸⁴ HME ⁷⁶	MCAP, MPPH ^{68,186}
<i>PIK3R2</i> <i>RAB39B</i>	*603157 *300774	Germline Germline, somatic	AD XL	GOF LOF	MEG, PMG ⁸² MEG ¹⁸⁷	MPPH ¹⁸⁶ ASD, ID ^{187,188}
<i>PTEN</i>	*601728	Germline, somatic	AD	LOF	HME, ^{84,189} MEG, ⁸⁹ FCD, ¹⁹⁰ PMG ¹⁹¹	ASD, ⁸⁹ Cowden syndrome ¹⁹²
<i>AKT1</i>	*164730	Germline, somatic	AD	GOF	HME, ¹⁰⁵ MEG ¹⁰⁴	Cowden syndrome, ⁶⁷ Proteus syndrome ¹⁰⁴
<i>AKT3</i>	*611223	Germline, somatic	AD	GOF	HME, ⁹⁸ MEG, ⁶⁸ PMG, ⁷⁰ FCDII ¹⁴²	MPPH, MCAP ^{68,186}
<i>PPP2R5D</i>	*601646	Germline	AD	LOF	MIC ^{106,107}	\
<i>PAK1</i>	*602590	Germline	AD	GOF	MEG ¹⁹³	ID ¹⁹⁴
<i>CCND2</i>	*123833	Germline	AD	GOF	MEG ¹¹³	IDDMSSD ¹¹³
<i>TSC1</i>	*605284	Germline, somatic	AD	LOF	MEG, ⁷⁹ PMG ⁵⁵ FCD, ¹⁴² TSC, ^{195,196} HME ^{142,196}	MCAP, MPPH ^{55,79} focal epilepsy ¹⁴²
<i>TSC2</i>	*191092	Germline, somatic	AD	LOF	FCD, ^{131,142} TSC, ^{131,142,195} HME ¹⁹⁶	focal epilepsy ¹⁴²
<i>STRADA</i>	*608626	Germline	AR	LOF	MEG ¹⁹⁷	PMSE ¹⁹⁷
<i>TBC1D7</i>	*612655	Germline	AR	LOF	MEG ^{198,199}	MGCPH, ID ^{198,199}
<i>RHEB</i>	*601293	Somatic	AD	GOF	HME, ¹⁴² FCDII, ¹⁵³	focal epilepsy, ¹⁴² ASD ¹⁵⁴
<i>DYRK1A</i>	*600855	Germline	AD	LOF	MIC ^{87,147}	ID, ¹⁴⁷ ASD ⁸⁷
<i>HERC1</i>	*605109	Germline	AR	GOF	MEG ¹⁴⁸	MDFPMR ¹⁴⁸
<i>MTOR</i>	*601231	Somatic germline	AD	GOF	MEG, ²⁰⁰ PMG, ²⁰¹ FCDII, ²⁰² HME ⁷⁵	Smith-Kingsmore syndrome ²⁰⁰
<i>RPS6</i>	*180460	Somatic	\	GOF	HME ²⁰³	HME with intractable epilepsy ²⁰³
<i>DEPDC5</i>	*614191	Germline, somatic	AD	LOF	HME, ⁷⁶ PMG, ²⁰⁴ FCDI, ²⁰⁵ FCDII ²⁰⁵	focal epilepsy, ²⁰⁵ FFEVF1
<i>NPRL3</i>	*600928	Germline, somatic	AD	LOF	HME, ²⁰⁶ PMG, ²⁰⁴ FCDII ²⁰⁷	FFEVF3 ²⁰⁴
<i>NPRL2</i>	*607072	Germline, somatic	AD	LOF	FCD, ^{204,208} PMG ²⁰⁴	FFEVF2 ²⁰⁴
<i>KPTN</i>	*615620	Germline	AR	LOF	MEG ^{178,179}	Familial intellectual disability-macrocephaly syndrome ^{178,179}
<i>SZT2</i>	*615463	Germline	AR	LOF	MEG ^{176,177}	Infantile encephalopathy with epilepsy ^{176,177}

Table 2 Summary of the mTOR inhibitors.

Drug category	mTOR inhibitors	Dosage	Phase
Antibiotic allosteric mTOR inhibitors	Rapamycin (Sirolimus or Rapamune)	Oral solution and tablet.	FDA approved
	Temsirolimus (Torisel/CCI-779)	Intravenous injection	FDA approved EMA approved
	Everolimus (Afinitor/RAD001)	Oral tablets	FDA approved
	Ridaforolimus (Deforolimus/AP23573/MK-8669)	Oral	Phase III ²⁴⁴
	Umirolimus (Biolimus/Biolimus A9/BA9/TRM-986)	Used in drug eluting stent	Phase IV ²⁴⁵
	Zotarolimus (ABT-578)	Used in drug-loading stent	Phase IV ²⁴⁶
	WYE-592	\	Not applicable
	ILS-920	Intravenous injection	Phase I ²⁴⁷
ATP-competitive mTOR inhibitors	Ku-0063794	\	Not applicable
	AZD8055	Oral solution or tablet	Phase I ²⁴⁸
	AZD2014 (Vistusertib)	Oral tablets	Phase II ²⁴⁹
	PP242	Oral	Preclinical Study ^{250,251}
	PP30	\	Not applicable
	PP487	\	Not applicable
	PP121	\	Not applicable
	Torin 1	\	Preclinical study ²⁵²
	Torin 2	Oral	Preclinical Study ^{253,254}
	OSI-027 (ASP7486)	Oral	Phase I ²⁵⁵
	CC-223 (Onatasertib)	Oral	Phase II ²⁵⁶
	XL388	Oral	Preclinical study ^{257,258}
	mTOR/PI3K dual inhibitors	PI-103	\
PKI-587 (Gedatolisib/PF-05212384)		Intravenous injection	Phase I ^{259,260}
PKI-179		\	Not applicable
KU-BMCL-200908069-1		\	Not applicable
PQR309 (Bimiralisib)		Oral	Phase II (available at https://www.hra.nhs.uk/) Preclinical study ²⁶¹
PQR514		Oral	Preclinical study ²⁶¹
WAY-001		\	Not applicable
WAY-600		\	Not applicable
WYE-687		\	Not applicable
WYE-354		\	Not applicable
WYE-132 (WYE-125132)		Oral	Preclinical study ²⁶²
Wyeth-BMCL-200910096-27		\	Not applicable
INK-128 (Sapanisertib/TAK-228/MLN0128)		Oral	Phase I ^{263,264}
GDC-0941 (Pctilisib)		Intramuscular injection and oral	Phase II ^{265,266}
GDC-0980 (Apatolisib/RG7422)		Intramuscular injection and oral	Phase II ^{266,267}
Wyeth-BMCL-200910075-9a-h		\	Not applicable
GNE-493		\	Not applicable
GNE-477		\	Not applicable
GSK2126458 (Omipalisib/GSK458)		Oral film-coated tablet	Phase I ^{268,269}
CMG002		Oral	Preclinical study ²⁷⁰
XL765 (Voxtalisib)	Oral	Phase II ²⁷¹	
NVP-BEZ235 (Dactolisib/BEZ235)	Oral	Phase III ²⁷²	
NVP-BGT226 (BGT226)	Oral	Preclinical study ²⁷³	
LY3023414	Oral	Phase II ^{274,275}	

Table 2 (continued)

Drug category	mTOR inhibitors	Dosage	Phase
Other new mTOR inhibitors	PKI-402	\	Preclinical study ²⁷⁶
	PF-04691502	Oral and intravenous administration	Phase II ²⁷⁷
	VS-5584 (SB2343)	Oral	Preclinical study ^{278,279}
	GDC-0084	Oral	Phase I ²⁸⁰
	Wortmannin	Intraperitoneal administration	Preclinical study ^{281,282}
	P529 (Palomid 529/RES-529)	Subconjunctival injection	Phase I ²⁸³
	JR-AB2-011	\	Not applicable
	RapaLink-1	Subcutaneous injection	Preclinical study ²⁸⁴
	RapaLink-2	\	Not applicable
	RapaLink-3	\	Not applicable
Natural products with mTOR inhibitory activity	Curcumin	Oral	Phase IV ²⁸⁵
	Epigallocatechin gallate (EGCG)	Oral	Phase IV ²⁸⁶
	Resveratrol (RSV)	Oral	Phase IV ²⁸⁷
	Sulforaphane (SFN)	Autism spectrum disorder	Phase II ²⁸⁸
	Cryptotanshinone (CPT)	\	Preclinical study ^{289,290}
	Genistein	Oral	Phase III ²⁹¹
	Caffeine	Oral and intravenous injection	FDA approved
	Salidroside (Rhodioloside)	\	Preclinical study ^{292,293}
	Oridonin (Rubescensin A)	\	Not applicable
	Capsaicin	Qutenza patch	FDA approved
	Arctigenin (ATG)	Intraperitoneally injection	Preclinical study ²⁹⁴
	Apigenin	\	Preclinical study ²⁹⁵
	Vitexin	Oral	Preclinical study ²⁹⁶
	Andrographolide	\	Preclinical study ^{297,298}
	Rotundic acid	\	Not applicable
Ginkgolic acid	\	Not applicable	
Afrocyclamin A	\	Not applicable	
Docetaxel	Injection concentrate	FDA approved	

exhibit typical morphological and functional features.^{227,228} Brain organoids carrying the *PTEN* mutation were constructed, and *PTEN* mutant human organoids grew larger than controls and developed complex surface folds. While the mouse brain is naturally lissencephalic, and *Pten* mutant mouse organoids developed with no surface folds, underscoring the need to develop human model systems.^{229,230} Recently, human brain organoids carrying the *TSC2* mutations also successfully showed the TSC phenotype. Furthermore, the study suggested that the hyperproliferation of caudal late interneuron progenitor cells resulted in brain tumors and cortical tubers.²³¹ Also, human brain organoids derived from pluripotent stem cells originating from patients with developmental or neurodegenerative brain diseases (e.g., MIC, lissencephaly, ASD) have been successfully constructed. They can mimic impaired neuronal migration, severe apoptosis of neural stem cells,

and defective division of outer radial glia cells.^{227,232,233} It is more beneficial to explore disease pathogenesis and discover potential drug targets.

Based on the characteristics of different models, the preferred models should be carefully considered when studying MCD disease phenotypes and mechanisms.

Disease therapy

With the advance of whole-exome sequencing and imaging technology, research on cortical developmental disorders was greatly accelerated. Exploring safer and more effective intervention strategies has gradually become a priority. Genetic factors associated with the PI3K/PTEN/AKT/mTOR pathway are important pathogenesis of MCD. Doctors will not be restricted by traditional symptomatic treatment,

such as antiepileptic drugs, stereotactic electroencephalography-mediated radiofrequency ablation, multiple subpial transections, bipolar electrocoagulation on functional cortex, neuromodulation techniques, and surgical excision of the lesions,^{234–236} but instead focus on the PI3K/PTEN/AKT/mTOR pathway targeting drugs for etiological treatment. For example, the mTOR inhibitor rapamycin is a targeted drug. It can acutely inhibit mTORC1 by binding it directly. Long-term treatment with rapamycin also can inhibit mTORC2. A possible mechanism is that rapamycin inhibits the assembly of the mTORC2 complex. Thereby, rapamycin can inhibit the abnormal hyperactivation of the pathway caused by mutations of related genes.^{237,238} Many studies reveal that rapamycin treatment can rescue neuronal migration defect, neuron overgrowth, brain enlargement, epilepsy, and development delay in animal models of MCD, such as *AKT*, *TSC*, *mTOR*, *PTEN*, *DEPDC5* deficiency mice.^{15,17,131,239–241} Currently, mTOR inhibitors mainly include antibiotic allosteric inhibitors, ATP-competitive inhibitors, mTOR/PI3K dual inhibitors, new inhibitors, and natural products. We summarize them in Table 2.²⁴² In addition, BYL719, a PIK3CA inhibitor that blocks the phosphorylation of AKT, may be a better-targeted drug. Since the therapeutic effect of BYL719 may be driven exclusively by blocking AKT, BYL719 may be an additional option for patients who fail to respond to rapamycin. Moreover, BYL719 does not show significant toxic effects and even improves the clinical symptoms of PIK3CA-related overgrowth spectrum patients better than rapamycin.²⁴³

Conclusions

Although we have much understanding of MCD, the high heterogeneity of MCD and the overlapping clinical phenotypes of different subtypes, in addition to some MCD in the form of syndromes, all together lead to a high rate of clinical underdiagnosis and misdiagnosis. It is necessary to continue to explore better diagnostic methods and to pay attention to genetic counseling and prenatal screening for MCD. There are many challenges ahead in screening and identifying the causative genes of MCD. More suitable disease models are needed to study the molecular mechanisms of known causative genes and related pathways and to design more effective and safe targeted drugs. Only through accurate diagnosis can patients receive optimal treatment, improve prognosis and living quality, and reduce public health costs.

Conflict of interests

The authors declare no conflict of interests.

Funding

This work was supported by the Tou-Yan Innovation Team Program of the Heilongjiang Province, China (No. 2019-15).

Acknowledgements

We thank Dr. Dekai Zhang for supporting this work.

References

- Harris J, Tomassy GS, Arlotto P. Building blocks of the cerebral cortex: from development to the dish. *Wiley Interdiscip Rev Dev Biol.* 2015;4(5):529–544.
- Guerrini R, Dobyns WB. Malformations of cortical development: clinical features and genetic causes. *Lancet Neurol.* 2014;13(7):710–726.
- Marsan E, Baulac S. Review: mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. *Neuropathol Appl Neurobiol.* 2018;44(1):6–17.
- Karalis V, Bateup HS. Current approaches and future directions for the treatment of mTORopathies. *Dev Neurosci.* 2021;43(3–4):143–158.
- Crino PB. mTOR signaling in epilepsy: insights from malformations of cortical development. *Cold Spring Harb Perspect Med.* 2015;5(4):a022442.
- Yasin SA, Ali AM, Tata M, et al. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. *Acta Neuropathol.* 2013;126(2):207–218.
- Dobyns WB, Mirzaa GM. Megalencephaly syndromes associated with mutations of core components of the PI3K-AKT-mTOR pathway: PIK3CA, PIK3R2, AKT3, and MTOR. *Am J Med Genet C Semin Med Genet.* 2019;181(4):582–590.
- Kumar M, Bansal N. Implications of phosphoinositide 3-kinase-akt (PI3K-akt) pathway in the pathogenesis of Alzheimer's disease. *Mol Neurobiol.* 2022;59(1):354–385.
- Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. *Cell.* 2017;168(6):960–976.
- Lipton JO, Sahin M. The neurology of mTOR. *Neuron.* 2014;84(2):275–291.
- Cepeda C, Levinson S, Yazon VW, et al. Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non-mTOR-mediated etiologies. *Epilepsia Open.* 2018;3(Suppl 2):180–190.
- Moloney PB, Cavalleri GL, Delanty N. Epilepsy in the mTORopathies: opportunities for precision medicine. *Brain Commun.* 2021;3(4):fcab222.
- Nguyen LH, Mahadeo T, Bordey A. mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental model of tuberous sclerosis complex and focal cortical dysplasia. *J Neurosci.* 2019;39(14):2762–2773.
- van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on drug management of refractory epilepsy in tuberous sclerosis complex. *Paediatr Drugs.* 2020;22(1):73–84.
- Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. *Nat Med.* 2015;21(4):395–400.
- Theilmann W, Gericke B, Schidlitzki A, et al. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. *Neuropharmacology.* 2020;180:108297.
- Nguyen LH, Brewster AL, Clark ME, et al. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. *Epilepsia.* 2015;56(4):636–646.
- Wesseling H, Elgersma Y, Bahn S. A brain proteomic investigation of rapamycin effects in the *Tsc1^{+/-}* mouse model. *Mol Autism.* 2017;8:41.
- Molnár Z, Clowry G. Cerebral cortical development in rodents and primates. *Prog Brain Res.* 2012;195:45–70.
- Nowakowski TJ, Pollen AA, Sandoval-Espinosa C, Kriegstein AR. Transformation of the radial *Glia* scaffold demarcates two stages of human cerebral cortex development. *Neuron.* 2016;91(6):1219–1227.

21. Kageyama R, Ochi S, Sueda R, Shimojo H. The significance of gene expression dynamics in neural stem cell regulation. *Proc Jpn Acad Ser B Phys Biol Sci.* 2020;96(8):351–363.
22. Ramos SI, Makeyev EV, Salierno M, Kodama T, Kawakami Y, Sahara S. Tuba8 drives differentiation of cortical radial *Glia* into apical intermediate progenitors by tuning modifications of tubulin C termini. *Dev Cell.* 2020;52(4):477–491.e8.
23. Taverna E, Götz M, Huttner WB. The cell biology of neurogenesis: toward an understanding of the development and evolution of the neocortex. *Annu Rev Cell Dev Biol.* 2014;30:465–502.
24. Silbereis JC, Pochareddy S, Zhu Y, Li M, Sestan N. The cellular and molecular landscapes of the developing human central nervous system. *Neuron.* 2016;89(2):248–268.
25. Lodato S, Arlotta P. Generating neuronal diversity in the mammalian cerebral cortex. *Annu Rev Cell Dev Biol.* 2015;31:699–720.
26. Mukhtar T, Taylor V. Untangling cortical complexity during development. *J Exp Neurosci.* 2018;12:1179069518759332.
27. Li J, Sun L, Peng XL, et al. Integrative genomic analysis of early neurogenesis reveals a temporal genetic program for differentiation and specification of preplate and Cajal-Retzius neurons. *PLoS Genet.* 2021;17(3):e1009355.
28. Terashima M, Ishikawa A, Männer J, Yamada S, Takakuwa T. Early development of the cortical layers in the human brain. *J Anat.* 2021;239(5):1039–1049.
29. Agirman G, Broix L, Nguyen L. Cerebral cortex development: an outside-in perspective. *FEBS Lett.* 2017;591(24):3978–3992.
30. Azzarelli R, Guillemot F, Pacary E. Function and regulation of Rnd proteins in cortical projection neuron migration. *Front Neurosci.* 2015;9:19.
31. Klingler E, Francis F, Jabaudon D, Cappello S. Mapping the molecular and cellular complexity of cortical malformations. *Science.* 2021;371(6527):eaba4517.
32. Kwan KY, Sestan N, Anton ES. Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. *Development.* 2012;139(9):1535–1546.
33. Vitalis T, Ansorge MS, Dayer AG. Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes. *Front Cell Neurosci.* 2013;7:93.
34. Mišićić T, Kostović I, Rašin MR, Krsnik Ž. Adult upper cortical layer specific transcription factor CUX2 is expressed in transient subplate and marginal zone neurons of the developing human brain. *Cells.* 2021;10(2):415.
35. Simons M, Nave KA. Oligodendrocytes: myelination and axonal support. *Cold Spring Harbor Perspect Biol.* 2015;8(1):a020479.
36. Figlia G, Gerber D, Suter U. Myelination and mTOR. *Glia.* 2018;66(4):693–707.
37. Baldwin KT, Silver DL. Expanding gliogenesis. *Science.* 2021;372(6547):1151–1152.
38. Allen NJ, Lyons DA. *Glia* as architects of central nervous system formation and function. *Science.* 2018;362(6411):181–185.
39. Barkovich AJ, Guerrini R, Kuzniecky RI, Jackson GD, Dobyns WB. A developmental and genetic classification for malformations of cortical development: update 2012. *Brain.* 2012;135(5):1348–1369.
40. Pirozzi F, Nelson B, Mirzaa G. From microcephaly to megalencephaly: determinants of brain size. *Dialogues Clin Neurosci.* 2018;20(4):267–282.
41. James J, Iype M, Surendran MO, Anitha A, Thomas SV. The genetic landscape of polymicrogyria. *Ann Indian Acad Neurol.* 2022;25(4):616–626.
42. Tahta A, Turgut M. Focal cortical dysplasia: etiology, epileptogenesis, classification, clinical presentation, imaging, and management. *Childs Nerv Syst.* 2020;36(12):2939–2947.
43. Blümcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. *Epilepsia.* 2011;52(1):158–174.
44. Oegema R, Barakat TS, Wilke M, et al. International consensus recommendations on the diagnostic work-up for malformations of cortical development. *Nat Rev Neurol.* 2020;16(11):618–635.
45. Mühlebner A, Bongaarts A, Sarnat HB, Scholl T, Aronica E. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives. *J Anat.* 2019;235(3):521–542.
46. Specchio N, Pepi C, De Palma L, Trivisano M, Vigevano F, Curatolo P. Neuroimaging and genetic characteristics of malformation of cortical development due to mTOR pathway dysregulation: clues for the epileptogenic lesions and indications for epilepsy surgery. *Expert Rev Neurother.* 2021;21(11):1333–1345.
47. Mühlebner A, van Scheppingen J, Hulshof HM, et al. Novel histopathological patterns in cortical tubers of epilepsy surgery patients with tuberous sclerosis complex. *PLoS One.* 2016;11(6):e0157396.
48. Islam MP. Tuberous sclerosis complex. *Semin Pediatr Neurol.* 2021;37:100875.
49. Gao W, Yang H, Huang W, Yang Y, Li D, Wei L. microRNA-29a-3p regulates SH-SY5Y cell proliferation and neurite growth through interaction with PTEN-PI3K/AKT/mTOR signaling pathway. *Dis Markers.* 2022;2022:8151161.
50. Guimaraes CVA, Dahmouh HM. Imaging phenotype correlation with molecular and molecular pathway defects in malformations of cortical development. *Pediatr Radiol.* 2020;50(13):1974–1987.
51. Tanaka S, Shimada N, Shiraki H, et al. GPR3 accelerates neurite outgrowth and neuronal polarity formation via PI₃ kinase-mediated signaling pathway in cultured primary neurons. *Mol Cell Neurosci.* 2022;118:103691.
52. Zhang XH, Shen CL, Wang XY, et al. Increased anxiety-like behaviors in *Adgr1*^{-/-} male but not female mice are attributable to elevated neuron dendrite density, upregulated PSD95 expression, and abnormal activation of the PI3K/AKT/GSK-3 β and MEK/ERK pathways. *Neuroscience.* 2022;503:131–145.
53. Osorio-Fuentealba C, Klip A. Dissecting signalling by individual Akt/PKB isoforms, three steps at once. *Biochem J.* 2015;470(2):e13–e16.
54. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. *Cell.* 2012;149(2):274–293.
55. Mirzaa G, Parry AE, et al. *De novo* CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome. *Nat Genet.* 2014;46(5):510–515.
56. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberlin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol Cell.* 2002;10(1):151–162.
57. Jhanwar-Uniyal M, Wainwright JV, Mohan AL, et al. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. *Adv Biol Regul.* 2019;72:51–62.
58. Fu W, Hall MN. Regulation of mTORC2 signaling. *Genes (Basel).* 2020;11(9):E1045.
59. Mukherjee R, Vanaja KG, Boyer JA, et al. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Mol Cell.* 2021;81(4):708–723.e5.
60. Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. *N Engl J Med.* 2018;379(21):2052–2062.

61. Starska K, Forma E, Lewy-Trenda I, Stasikowska-Kanicka O, Skóra M, Bryś M. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer. *Cell Oncol.* 2018;41(3):253–268.
62. González-García A, Garrido A, Carrera AC. Targeting PTEN regulation by post translational modifications. *Cancers (Basel).* 2022;14(22):5613.
63. Wei Y, Zhou J, Yu H, Jin X. AKT phosphorylation sites of Ser473 and Thr308 regulate AKT degradation. *Biosci Biotechnol Biochem.* 2019;83(3):429–435.
64. Zhang W, Ma L, Yang M, et al. Cerebral organoid and mouse models reveal a RAB39b-PI3K-mTOR pathway-dependent dysregulation of cortical development leading to macrocephaly/autism phenotypes. *Genes Dev.* 2020;34(7–8):580–597.
65. Di Donato N, Rump A, Mirzaa GM, et al. Identification and characterization of a novel constitutional PIK3CA mutation in a child lacking the typical segmental overgrowth of "PIK3CA-related overgrowth spectrum". *Hum Mutat.* 2016;37(3):242–245.
66. Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. *Orphanet J Rare Dis.* 2021;16(1):306.
67. Orloff MS, He X, Peterson C, et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. *Am J Hum Genet.* 2013;92(1):76–80.
68. Rivière JB, Mirzaa GM, O'Roak BJ, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet.* 2012;44(8):934–940.
69. Cheung LWT, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discov.* 2011;1(2):170–185.
70. Nakamura K, Kato M, Tohyama J, et al. AKT3 and PIK3R2 mutations in two patients with megalencephaly-related syndromes: MCAP and MPPH. *Clin Genet.* 2014;85(4):396–398.
71. Terrone G, Voisin N, Abdullah Alfaiz A, et al. De novo PIK3R2 variant causes polymicrogyria, corpus callosum hyperplasia and focal cortical dysplasia. *Eur J Hum Genet.* 2016;24(9):1359–1362.
72. Zhu H, Zhang W, Zhao Y, et al. GSK3 β -mediated tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions. *Mol Neurodegener.* 2018;13(1):1–17.
73. Xu ZX, Kim GH, Tan JW, et al. Elevated protein synthesis in microglia causes autism-like synaptic and behavioral aberrations. *Nat Commun.* 2020;11:1797.
74. Keppler-Noreuil KM, Rios JJ, Parker VER, et al. PIK3CA-related overgrowth spectrum (PROS):diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A.* 2015;167A(2):287–295.
75. Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet.* 2012;44(8):941–945.
76. D'Gama AM, Geng Y, Couto JA, et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. *Ann Neurol.* 2015;77(4):720–725.
77. Swarr DT, Khalek N, Treat J, et al. Expanding the differential diagnosis of fetal hydrops: an unusual prenatal presentation of megalencephaly-capillary malformation syndrome. *Prenat Diagn.* 2013;33(10):1010–1012.
78. Kinross KM, Montgomery KG, Mangiafico SP, et al. Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly. *Faseb J.* 2015;29(4):1426–1434.
79. McDermott JH, Hickson N, Banerjee I, et al. Hypoglycaemia represents a clinically significant manifestation of PIK3CA- and CCND2-associated segmental overgrowth. *Clin Genet.* 2018;93(3):687–692.
80. Davis S, Ware MA, Zeiger J, et al. Growth hormone deficiency in megalencephaly-capillary malformation syndrome: an association with activating mutations in PIK3CA. *Am J Med Genet A.* 2020;182(1):162–168.
81. Hanafusa H, Morisada N, Nomura T, et al. A girl with CLOVES syndrome with a recurrent PIK3CA somatic mutation and pancreatic steatosis. *Hum Genome Var.* 2019;6:31.
82. Mirzaa GM, Conti V, Timms AE, et al. Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study. *Lancet Neurol.* 2015;14(12):1182–1195.
83. Negishi Y, Miya F, Hattori A, et al. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly. *BMC Med Genet.* 2017;18(1):4.
84. Jansen LA, Mirzaa GM, Ishak GE, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. *Brain.* 2015;138(Pt 6):1613–1628.
85. Lim KC, Crino PB. Focal malformations of cortical development: new vistas for molecular pathogenesis. *Neuroscience.* 2013;252:262–276.
86. Schick V, Majores M, Engels G, et al. Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias. *Acta Neuropathol.* 2006;112(6):715–725.
87. O'Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science.* 2012;338(6114):1619–1622.
88. Jin SC, Dong W, Kundishora AJ, et al. Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus. *Nat Med.* 2020;26(11):1754–1765.
89. Kaymakçalan H, Kaya İ, Cevher Binici N, et al. Prevalence and clinical/molecular characteristics of PTEN mutations in Turkish children with autism spectrum disorders and macrocephaly. *Mol Genet Genomic Med.* 2021;9(8):e1739.
90. Huang WC, Chen Y, Page DT. Hyperconnectivity of prefrontal cortex to amygdala projections in a mouse model of macrocephaly/autism syndrome. *Nat Commun.* 2016;7:13421.
91. Skelton PD, Stan RV, Luikart BW. The role of PTEN in neurodevelopment. *Mol Neuropsychiatry.* 2020;5(Suppl 1):60–71.
92. Igarashi A, Kato T, Sesaki H, Iijima M. Nuclear PTEN deficiency and heterozygous PTEN loss have distinct impacts on brain and lymph node size. *Biochem Biophys Res Commun.* 2021;555:81–88.
93. Lyu J, Yu X, He L, et al. The protein phosphatase activity of PTEN is essential for regulating neural stem cell differentiation. *Mol Brain.* 2015;8:26.
94. Chen F, Rosiene J, Che A, Becker A, LoTurco J. Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling. *Development.* 2015;142(20):3601–3611.
95. Vogt D, Cho KKA, Lee AT, Sohal VS, Rubenstein JLR. The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles. *Cell Rep.* 2015;11(6):944–956.
96. Clipperton-Allen AE, Zhang A, Cohen OS, Page DT. Environmental enrichment rescues social behavioral deficits and synaptic abnormalities in Pten haploinsufficient mice. *Genes (Basel).* 2021;12(9):1366.
97. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. *Development.* 2005;132(13):2943–2954.

98. Poduri A, Evrony GD, Cai X, et al. Somatic activation of *AKT3* causes hemispheric developmental brain malformations. *Neuron*. 2012;74(1):41–48.
99. Alcantara D, Timms AE, Gripp K, et al. Mutations of *AKT3* are associated with a wide spectrum of developmental disorders including extreme megalencephaly. *Brain*. 2017;140(10):2610–2622.
100. Wang D, Zeeman S, Tarnopolsky MA, Nowaczyk MJ. Duplication of *AKT3* as a cause of macrocephaly in duplication 1q43q44. *Am J Med Genet A*. 2013;161A(8):2016–2019.
101. Lopes F, Torres F, Soares G, et al. The role of *AKT3* copy number changes in brain abnormalities and neurodevelopmental disorders: four new cases and literature review. *Front Genet*. 2019;10:58.
102. Nellist M, Schot R, Hoogeveen-Westerveld M, et al. Germline activating *AKT3* mutation associated with megalencephaly, polymicrogyria, epilepsy and hypoglycemia. *Mol Genet Metabol*. 2015;114(3):467–473.
103. Takagi M, Dobashi K, Nagahara K, et al. A novel *de novo* germline mutation Glu40Lys in *AKT3* causes megalencephaly with growth hormone deficiency. *Am J Med Genet A*. 2017;173(4):1071–1076.
104. Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in *AKT1* associated with the *Proteus* syndrome. *N Engl J Med*. 2011;365(7):611–619.
105. D’Gama AM, Woodworth MB, Hossain AA, et al. Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias. *Cell Rep*. 2017;21(13):3754–3766.
106. Ballif BC, Rosenfeld JA, Traylor R, et al. High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. *Hum Genet*. 2012;131(1):145–156.
107. Lloveras E, Canellas A, Barranco L, et al. A new case with corpus callosum abnormalities, microcephaly and seizures associated with a 2.3-mb 1q43-q44 deletion. *Cytogenet Genome Res*. 2019;159(3):126–129.
108. Ciaccio C, Cellini E, Guerrini R, Pantaleoni C, Masson R. Mirror syndromes regarding *AKT3* mutations: loss of function variant leading to microcephaly. *Am J Med Genet A*. 2020;182(11):2800–2802.
109. Tokuda S, Mahaffey CL, Monks B, et al. A novel *Akt3* mutation associated with enhanced kinase activity and seizure susceptibility in mice. *Hum Mol Genet*. 2011;20(5):988–999.
110. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. *J Hepatol*. 2010;52(1):88–95.
111. Papke CM, Smolen KA, Swingle MR, et al. A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth. *J Biol Chem*. 2021;296:100313.
112. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. *Nature*. 2015;519(7542):223–228.
113. Harms FL, Kloth K, Bley A, et al. Activating mutations in *PAK1*, encoding p21-activated kinase 1, cause a neurodevelopmental disorder. *Am J Hum Genet*. 2018;103(4):579–591.
114. Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. *Cell Biosci*. 2020;10(1):54.
115. Duda P, Akula SM, Abrams SL, et al. Targeting GSK3 and associated signaling pathways involved in cancer. *Cells*. 2020;9(5):1110.
116. Peretto M, Xu X, Lu C, et al. The RNA helicase *DDX3* induces neural crest by promoting AKT activity. *Development*. 2021;148(2):dev184341.
117. Kida A, Kakihana K, Kotani S, Kurosu T, Miura O. Glycogen synthase kinase-3 β and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells. *Oncogene*. 2007;26(46):6630–6640.
118. Kim WY, Wang X, Wu Y, et al. GSK-3 is a master regulator of neural progenitor homeostasis. *Nat Neurosci*. 2009;12(11):1390–1397.
119. Glickstein SB, Monaghan JA, Koeller HB, Jones TK, Ross ME. Cyclin D2 is critical for intermediate progenitor cell proliferation in the embryonic cortex. *J Neurosci*. 2009;29(30):9614–9624.
120. Manandhar S, Sankhe R, Priya K, et al. Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer’s disease. *Mol Divers*. 2022;26(5):2793–2811.
121. Reijnders MRF, Ansor NM, Kousi M, et al. *RAC1* missense mutations in developmental disorders with diverse phenotypes. *Am J Hum Genet*. 2017;101(3):466–477.
122. Snijders Blok L, Madsen E, Juusola J, et al. Mutations in *DDX3X* are a common cause of unexplained intellectual disability with gender-specific effects on Wnt signaling. *Am J Hum Genet*. 2015;97(2):343–352.
123. Maini I, Farnetti E, Caraffi SG, et al. A novel *CCND2* mutation in a previously reported case of megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and *Hydrocephalus*. *Neuropediatrics*. 2018;49(3):222–224.
124. Dibble CC, Elis W, Menon S, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. *Mol Cell*. 2012;47(4):535–546.
125. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. *Biochem J*. 2008;412(2):179–190.
126. Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. *Nature*. 2017;552(7685):368–373.
127. Mallela K, Kumar A. Role of TSC1 in physiology and diseases. *Mol Cell Biochem*. 2021;476(6):2269–2282.
128. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. *Trends Mol Med*. 2013;19(1):51–60.
129. Zeqiraj E, Filippi BM, Goldie S, et al. ATP and MO25 α regulate the conformational state of the STRAD α pseudokinase and activation of the LKB1 tumour suppressor. *PLoS Biol*. 2009;7(6):e1000126.
130. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol*. 2007;8(10):774–785.
131. Lim JS, Gopalappa R, Kim SH, et al. Somatic mutations in *TSC1* and *TSC2* cause focal cortical dysplasia. *Am J Hum Genet*. 2017;100(3):454–472.
132. Wang MX, Segaran N, Bhalla S, et al. Tuberous sclerosis: current update. *Radiographics*. 2021;41(7):1992–2010.
133. Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. *Nat Rev Dis Prim*. 2016;2:16035.
134. D’Gama AM, Poduri A. Precision therapy for epilepsy related to brain malformations. *Neurotherapeutics*. 2021;18(3):1548–1563.
135. Donkels C, Peters M, Fariña Núñez MT, et al. Oligodendrocyte lineage and myelination are compromised in the gray matter of focal cortical dysplasia type IIa. *Epilepsia*. 2020;61(1):171–184.
136. Scholl T, Mühlebner A, Ricken G, et al. Impaired oligodendroglial turnover is associated with myelin pathology in focal cortical dysplasia and tuberous sclerosis complex. *Brain Pathol*. 2017;27(6):770–780.
137. Meikle L, Talos DM, Onda H, et al. A mouse model of tuberous sclerosis: neuronal loss of *Tsc1* causes dysplastic and ectopic

- neurons, reduced myelination, seizure activity, and limited survival. *J Neurosci.* 2007;27(21):5546–5558.
138. Carson RP, Kelm ND, West KL, et al. Hypomyelination following deletion of Tsc2 in oligodendrocyte precursors. *Ann Clin Transl Neurol.* 2015;2(12):1041–1054.
 139. Gruber VE, Lang J, Endmayr V, et al. Impaired myelin production due to an intrinsic failure of oligodendrocytes in mTOR-pathies. *Neuropathol Appl Neurobiol.* 2021;47(6):812–825.
 140. Crino PB, Aronica E, Baltuch G, Nathanson KL. Biallelic TSC gene inactivation in tuberous sclerosis complex. *Neurology.* 2010;74(21):1716–1723.
 141. Qin W, Chan JA, Vinters HV, et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. *Brain Pathol.* 2010;20(6):1096–1105.
 142. Baldassari S, Ribierre T, Marsan E, et al. Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. *Acta Neuropathol.* 2019;138(6):885–900.
 143. Lee WS, Baldassari S, Stephenson SEM, Lockhart PJ, Baulac S, Leventer RJ. Cortical dysplasia and the mTOR pathway: how the study of human brain tissue has led to insights into epileptogenesis. *Int J Mol Sci.* 2022;23(3):1344.
 144. Hino O, Kobayashi T, Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. *Cancer Sci.* 2017;108(1):5–11.
 145. Menon VR, Litovchick L. DYRK1A kinase regulates mTOR signaling via modulating the TSC complex. [abstract]. In: proceedings of the 106th Annual Meeting of the American association for cancer research; 2015 Apr 18–22; philadelphia, PA. Philadelphia (PA): AACR. *Cancer Res.* 2015;75(15 Suppl). Abstract nr 1022.
 146. Larsen LJ, Møller LB. Crosstalk of hedgehog and mTORC1 pathways. *Cells.* 2020;9(10):2316.
 147. van Bon BW, Hoischen A, Hehir-Kwa J, et al. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. *Clin Genet.* 2011;79(3):296–299.
 148. Schwarz JM, Pedrazza L, Stenzel W, Rosa JL, Schuelke M, Straussberg R. A new homozygous HERC1 gain-of-function variant in MDFPMR syndrome leads to mTORC1 hyperactivation and reduced autophagy during cell catabolism. *Mol Genet Metabol.* 2020;131(1–2):126–134.
 149. Aggarwal S, Bhowmik AD, Ramprasad VL, Murugan S, Dalal A. A splice site mutation in HERC1 leads to syndromic intellectual disability with macrocephaly and facial dysmorphism: further delineation of the phenotypic spectrum. *Am J Med Genet A.* 2016;170(7):1868–1873.
 150. Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. *Trends Cell Biol.* 2015;25(9):545–555.
 151. Bai X, Ma D, Liu A, et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. *Science.* 2007;318(5852):977–980.
 152. Ma D, Bai X, Guo S, Jiang Y. The switch I region of Rheb is critical for its interaction with FKBP38. *J Biol Chem.* 2008;283(38):25963–25970.
 153. Zhao S, Li Z, Zhang M, et al. A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II. *Exp Mol Med.* 2019;51(7):1–11.
 154. Reijnders MRF, Kousi M, van Woerden GM, et al. Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability. *Nat Commun.* 2017;8:1052.
 155. Salinas V, Vega P, Piccirilli MV, et al. Identification of a somatic mutation in the RHEB gene through high depth and ultra-high depth next generation sequencing in a patient with Hemimegalencephaly and drug resistant Epilepsy. *Eur J Med Genet.* 2019;62(11):103571.
 156. Lee WS, Baldassari S, Chipaux M, et al. Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia. *Ann Clin Transl Neurol.* 2021;8(2):485–490.
 157. Goorden SM, Abs E, Bruinsma CF, Riemsdijk FW, van Woerden GM, Elgersma Y. Intact neuronal function in Rheb1 mutant mice: implications for TORC1-based treatments. *Hum Mol Genet.* 2015;24(12):3390–3398.
 158. Proietti Onori M, Koene LMC, Schäfer CB, et al. RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity. *PLoS Biol.* 2021;19(5):e3001279.
 159. Hsieh LS, Wen JH, Claycomb K, et al. Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement. *Nat Commun.* 2016;7:11753.
 160. Yang M, Lu Y, Piao W, Jin H. The translational regulation in mTOR pathway. *Biomolecules.* 2022;12(6):802.
 161. Lewis V, Rodrigue B, Arseneault E, et al. Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders. *J Neurochem.* 2023;166(1):10–23.
 162. Tsukumo Y, Alain T, Fonseca BD, Nadon R, Sonenberg N. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3. *Nat Commun.* 2016;7:11776.
 163. Wiebe S, Nagpal A, Truong VT, et al. Inhibitory interneurons mediate autism-associated behaviors via 4E-BP2. *Proc Natl Acad Sci U S A.* 2019;116(36):18060–18067.
 164. Chauvin C, Koka V, Nouschi A, et al. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. *Oncogene.* 2014;33(4):474–483.
 165. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. *Biochem J.* 2012;441(1):1–21.
 166. Blumcke I, Budday S, Poduri A, Lal D, Kobow K, Baulac S. Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. *Lancet Neurol.* 2021;20(11):943–955.
 167. Wolfson RL, Chantranupong L, Wyant GA, et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. *Nature.* 2017;543(7645):438–442.
 168. Gu X, Orozco JM, Saxton RA, et al. SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway. *Science.* 2017;358(6364):813–818.
 169. Baldassari S, Licchetta L, Tinuper P, Bisulli F, Pippucci T. GATOR1 complex: the common genetic actor in focal epilepsies. *J Med Genet.* 2016;53(8):503–510.
 170. Mroske C, Rasmussen K, Shinde DN, et al. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities. *BMC Med Genet.* 2015;16:102.
 171. Nakashima M, Saito H, Takei N, et al. Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb. *Ann Neurol.* 2015;78(3):375–386.
 172. Grabiner BC, Nardi V, Birsoy K, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. *Cancer Discov.* 2014;4(5):554–563.
 173. Smith LD, Saunders CJ, Dinwiddie DL, et al. Exome sequencing reveals *de novo* germline mutation of the mammalian target of rapamycin (MTOR) in a patient with megalencephaly and intractable seizures. *J Genomes Exomes.* 2013;2:63–72.
 174. Baldassari S, Picard F, Verbeek NE, et al. The landscape of epilepsy-related GATOR1 variants. *Genet Med.* 2019;21(2):398–408.
 175. Iffland II PH, Carson V, Bordey A, Crino PB. GATORopathies: the role of amino acid regulatory gene mutations in epilepsy and cortical malformations. *Epilepsia.* 2019;60(11):2163–2173.

176. Basel-Vanagaite L, Hershkovitz T, Heyman E, et al. Biallelic *SZT2* mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum. *Am J Hum Genet.* 2013;93(3):524–529.
177. Venkatesan C, Angle B, Millichap JJ. Early-life epileptic encephalopathy secondary to *SZT2* pathogenic recessive variants. *Epileptic Disord.* 2016;18(2):195–200.
178. Baple EL, Maroofian R, Chioza BA, et al. Mutations in *KPTN* cause macrocephaly, neurodevelopmental delay, and seizures. *Am J Hum Genet.* 2014;94(1):87–94.
179. Pajusalu S, Reimand T, Öunap K. Novel homozygous mutation in *KPTN* gene causing a familial intellectual disability-macrocephaly syndrome. *Am J Med Genet A.* 2015;167A(8):1913–1915.
180. Cormack AM, Sharpe C, Gregersen N, et al. 12q14 microdeletions: additional case series with confirmation of a macrocephaly region. *Case Rep Genet.* 2015;2015:192071.
181. Ribierre T, Deleuze C, Bacq A, et al. Second-hit mosaic mutation in mTORC1 repressor *DEPDC5* causes focal cortical dysplasia-associated epilepsy. *J Clin Invest.* 2018;128(6):2452–2458.
182. Ishii A, Furusho M, Macklin W, Bansal R. Independent and cooperative roles of the Mek/ERK1/2-MAPK and PI3K/Akt/mTOR pathways during developmental myelination and in adulthood. *Glia.* 2019;67(7):1277–1295.
183. Crino PB. mTOR: A pathogenic signaling pathway in developmental brain malformations. *Trends Mol Med.* 2011;17(12):734–742.
184. Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. *Expert Rev Neurother.* 2013;13(6):627–638.
185. Mirzaa G, Timms AE, Conti V, et al. *PIK3CA*-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. *JCI Insight.* 2016;1(9):e87623.
186. Mirzaa GM, Conway RL, Gripp KW, et al. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. *Am J Med Genet A.* 2012;158A(2):269–291.
187. Giannandrea M, Bianchi V, Mignogna ML, et al. Mutations in the small GTPase gene *RAB39B* are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. *Am J Hum Genet.* 2010;86(2):185–195.
188. Mignogna ML, Ficarella R, Gelmini S, et al. Clinical characterization of a novel *RAB39B* nonstop mutation in a family with ASD and severe ID causing *RAB39B* downregulation and study of a *Rab39b* knock down mouse model. *Hum Mol Genet.* 2022;31(9):1389–1406.
189. Koboldt DC, Miller KE, Miller AR, et al. PTEN somatic mutations contribute to spectrum of cerebral overgrowth. *Brain.* 2021;144(10):2971–2978.
190. Child ND, Cascino GD. Mystery case: Cowden syndrome presenting with partial epilepsy related to focal cortical dysplasia. *Neurology.* 2013;81(13):e98–e99.
191. Shao DD, Achkar CM, Lai A, et al. Polymicrogyria is associated with pathogenic variants in *PTEN*. *Ann Neurol.* 2020;88(6):1153–1164.
192. Arai H, Akagi K, Nakagawa A, et al. Clinical and genetic diagnosis of Cowden syndrome: a case report of a rare *PTEN* germline variant and diverse clinical presentation. *Medicine (Baltim).* 2023;102(1):e32572.
193. Loveday C, Tatton-Brown K, Clarke M, et al. Mutations in the PP2A regulatory subunit B family genes *PPP2R5B*, *PPP2R5C* and *PPP2R5D* cause human overgrowth [published correction appears in *Hum Mol Genet.* 2019 May 1;28(9):1578]. *Hum Mol Genet.* 2015;24(17):4775–4779.
194. Houge G, Haesen D, Vissers LE, et al. B56 δ -related protein phosphatase 2A dysfunction identified in patients with intellectual disability. *J Clin Invest.* 2015;125(8):3051–3062.
195. Tyburczy ME, Dies KA, Glass J, et al. Mosaic and intronic mutations in *TSC1/TSC2* explain the majority of TSC patients with no mutation identified by conventional testing. *PLoS Genet.* 2015;11(11):e1005637.
196. Sidira C, Vargiami E, Dragoumi P, Zafeiriou DI. Hemimegalencephaly and tuberous sclerosis complex: a rare yet challenging association. *Eur J Paediatr Neurol.* 2021;30:58–65.
197. Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. *Sci Transl Med.* 2013;5(182):182ra53.
198. Alfaiz AA, Micale L, Mandriani B, et al. *TBC1D7* mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. *Hum Mutat.* 2014;35(4):447–451.
199. Capo-Chichi JM, Tcherkezian J, Hamdan FF, et al. Disruption of *TBC1D7*, a subunit of the *TSC1-TSC2* protein complex, in intellectual disability and megalencephaly. *J Med Genet.* 2013;50(11):740–744.
200. Gordo G, Tenorio J, Arias P, et al. mTOR mutations in Smith-Kingsmore syndrome: four additional patients and a review. *Clin Genet.* 2018;93(4):762–775.
201. Mirzaa GM, Campbell CD, Solovieff N, et al. Association of *MTOR* mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism. *JAMA Neurol.* 2016;73(7):836–845.
202. Møller RS, Weckhuysen S, Chipaux M, et al. Germline and somatic mutations in the *MTOR* gene in focal cortical dysplasia and epilepsy. *Neurol Genet.* 2016;2(6):e118.
203. Pelorosso C, Watrin F, Conti V, et al. Somatic double-hit in *MTOR* and *RPS6* in hemimegalencephaly with intractable epilepsy. *Hum Mol Genet.* 2019;28(22):3755–3765.
204. Ricos MG, Hodgson BL, Pippucci T, et al. Mutations in the mammalian target of rapamycin pathway regulators *NPRL2* and *NPRL3* cause focal epilepsy. *Ann Neurol.* 2016;79(1):120–131.
205. Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to *DEPDC5* mutations. *Ann Neurol.* 2015;77(4):675–683.
206. Canavati C, Klein KM, Afawi Z, et al. Inclusion of hemimegalencephaly into the phenotypic spectrum of *NPRL3* pathogenic variants in familial focal epilepsy with variable foci. *Epilepsia.* 2019;60(6):e67–e73.
207. Sim JC, Scerri T, Fanjul-Fernández M, et al. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator *NPRL3*. *Ann Neurol.* 2016;79(1):132–137.
208. Weckhuysen S, Marsan E, Lambrecq V, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. *Epilepsia.* 2016;57(6):994–1003.
209. Abdel Razek AA, Kandell AY, Elsorogy LG, Elmongy A, Basett AA. Disorders of cortical formation: MR imaging features. *AJNR Am J Neuroradiol.* 2009;30(1):4–11.
210. Blondiaux E, Garel C. Fetal cerebral imaging - ultrasound vs. MRI: an update. *Acta Radiol.* 2013;54(9):1046–1054.
211. Cellini E, Vetro A, Conti V, et al. Multiple genomic copy number variants associated with periventricular nodular heterotopia indicate extreme genetic heterogeneity. *Eur J Hum Genet.* 2019;27(6):909–918.
212. Boonsawat P, Joset P, Steindl K, et al. Elucidation of the phenotypic spectrum and genetic landscape in primary and secondary microcephaly. *Genet Med.* 2019;21(9):2043–2058.
213. Silverman JL, Yang M, Lord C, Crawley JN. Behavioural phenotyping assays for mouse models of autism. *Nat Rev Neurosci.* 2010;11(7):490–502.
214. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. *Nat Neurosci.* 2010;13(10):1161–1169.

215. Dummler B, Tschopp O, Hynx D, Yang ZZ, Dirnhofer S, Hemmings BA. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. *Mol Cell Biol*. 2006;26(21):8042–8051.
216. Roy A, Skibo J, Kalume F, et al. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. *Elife*. 2015;4:e12703.
217. Shi X, Lim Y, Myers AK, et al. PIK3R2/Pik3r2 activating mutations result in brain overgrowth and EEG changes. *Ann Neurol*. 2020;88(6):1077–1094.
218. Huang W, Zhou Z, Asrar S, Henkelman M, Xie W, Jia Z. p21-activated kinases 1 and 3 control brain size through coordinating neuronal complexity and synaptic properties. *Mol Cell Biol*. 2011;31(3):388–403.
219. Jedynak P, Jaholkowski P, Wozniak G, Sandi C, Kaczmarek L, Filipkowski RK. Lack of cyclin D2 impairing adult brain neurogenesis alters hippocampal-dependent behavioral tasks without reducing learning ability. *Behav Brain Res*. 2012;227(1):159–166.
220. Mizuguchi M, Ohsawa M, Kashii H, Sato A. Brain symptoms of tuberous sclerosis complex: pathogenesis and treatment. *Int J Mol Sci*. 2021;22(13):6677.
221. Dang LT, Glanowska KM, Iffland Ii PH, et al. Multimodal analysis of STRADA function in brain development. *Front Cell Neurosci*. 2020;14:122.
222. Levy JA, LaFlamme CW, Tsapraillis G, Crynen G, Page DT. Dyrk1a mutations cause undergrowth of cortical pyramidal neurons via dysregulated growth factor signaling. *Biol Psychiatry*. 2021;90(5):295–306.
223. Yuskaitis CJ, Jones BM, Wolfson RL, et al. A mouse model of DEPDC5-related epilepsy: neuronal loss of *Depdc5* causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. *Neurobiol Dis*. 2018;111:91–101.
224. Sjöstedt E, Zhong W, Fagerberg L, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. *Science*. 2020;367(6482):eaay5947.
225. Li Y, Cao J, Chen M, et al. Abnormal neural progenitor cells differentiated from induced pluripotent stem cells partially mimicked development of *TSC2* neurological abnormalities. *Stem Cell Rep*. 2017;8(4):883–893.
226. Nadadthur AG, Alsaqati M, Gasparotto L, et al. Neuron-Glia interactions increase neuronal phenotypes in tuberous sclerosis complex patient iPSC-derived models. *Stem Cell Rep*. 2019;12(1):42–56.
227. Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. *Nature*. 2013;501(7467):373–379.
228. Schutgens F, Clevers H. Human organoids: tools for understanding biology and treating diseases. *Annu Rev Pathol*. 2020;15:211–234.
229. Di Lullo E, Kriegstein AR. The use of brain organoids to investigate neural development and disease. *Nat Rev Neurosci*. 2017;18(10):573–584.
230. Li Y, Muffat J, Omer A, et al. Induction of expansion and folding in human cerebral organoids. *Cell Stem Cell*. 2017;20(3):385–396.e3.
231. Eichmüller OL, Corsini NS, Vértesy Á, et al. Amplification of human interneuron progenitors promotes brain tumors and neurological defects. *Science*. 2022;375(6579):eabf5546.
232. Bershteyn M, Nowakowski TJ, Pollen AA, et al. Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. *Cell Stem Cell*. 2017;20(4):435–449.e4.
233. Mariani J, Coppola G, Zhang P, et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. *Cell*. 2015;162(2):375–390.
234. Englot DJ. A modern epilepsy surgery treatment algorithm: incorporating traditional and emerging technologies. *Epilepsy Behav*. 2018;80:68–74.
235. Zhai F, Zhou J, Li T, Cui Z, Luan G. Outcome of bipolar electrocoagulation with lesionectomy in the treatment of epilepsy involving eloquent areas. *Stereotact Funct Neurosurg*. 2015;93(1):1–9.
236. Frye RE, Rossignol D, Casanova MF, et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. *Front Public Health*. 2013;1:31.
237. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science*. 2012;335(6076):1638–1643.
238. Schreiber KH, Ortiz D, Academia EC, Anies AC, Liao CY, Kennedy BK. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. *Aging Cell*. 2015;14(2):265–273.
239. Baek ST, Copeland B, Yun EJ, et al. An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development. *Nat Med*. 2015;21(12):1445–1454.
240. Goto J, Talos DM, Klein P, et al. Regulable neural progenitor-specific *Tsc1* loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. *Proc Natl Acad Sci U S A*. 2011;108(45):E1070–E1079.
241. Marsan E, Ishida S, Schramm A, et al. *Depdc5* knockout rat: a novel model of mTORopathy. *Neurobiol Dis*. 2016;89:180–189.
242. Chen Y, Zhou X. Research progress of mTOR inhibitors. *Eur J Med Chem*. 2020;208:112820.
243. Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. *Nature*. 2018;558(7711):540–546.
244. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. *J Clin Oncol*. 2013;31(19):2485–2492.
245. Råber L, Yamaji K, Kelbæk H, et al. Five-year clinical outcomes and intracoronary imaging findings of the COMFORT-ABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. *Eur Heart J*. 2019;40(24):1909–1919.
246. Coughlan JJ, Aytakin A, Xhepa E, et al. Target and non-target vessel related events at 10 years post percutaneous coronary intervention. *Clin Res Cardiol*. 2022;111(7):787–794.
247. Ruan B, Pong K, Jow F, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. *Proc Natl Acad Sci U S A*. 2008;105(1):33–38.
248. Asahina H, Nokihara H, Yamamoto N, et al. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. *Invest New Drugs*. 2013;31(3):677–684.
249. Powles T, Wheeler M, Din O, et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. *Eur Urol*. 2016;69(3):450–456.
250. Zhou K, Chen X, Zhang L, et al. Targeting peripheral immune organs with self-assembling prodrug nanoparticles ameliorates allogeneic heart transplant rejection. *Am J Transplant*. 2021;21(12):3871–3882.
251. Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. *Gynecol Oncol*. 2014;132(2):468–473.

252. Duarte A, André-Grégoire G, Trillet K, et al. Inhibition of mTOR in head and neck cancer cells alters endothelial cell morphology in a paracrine fashion. *Mol Carcinog.* 2019;58(1):161–168.
253. Sun Y, Berleth N, Wu W, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. *Cell Death Dis.* 2021;12(11):1028.
254. Simioni C, Cani A, Martelli AM, et al. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. *Oncotarget.* 2014;5(20):10034–10047.
255. Bhagwat SV, Gokhale PC, Crew AP, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. *Mol Cancer Therapeut.* 2011;10(8):1394–1406.
256. Wolin E, Mita A, Mahipal A, et al. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. *PLoS One.* 2019;14(9):e0221994.
257. Xiong Z, Zang Y, Zhong S, et al. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. *Oncotarget.* 2017;8(18):30151–30161.
258. Zhu YR, Zhou XZ, Zhu LQ, et al. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. *Oncotarget.* 2016;7(31):49527–49538.
259. Houk BE, Alvey CW, Visswanathan R, et al. Distribution, metabolism, and excretion of gedatolisib in healthy male volunteers after a single intravenous infusion. *Clin Pharmacol Drug Dev.* 2019;8(1):22–31.
260. Shapiro GI, Bell-McGuinn KM, Molina JR, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. *Clin Cancer Res.* 2015;21(8):1888–1895.
261. Borsari C, Rageot D, Beauflis F, et al. Preclinical development of PQR514, a highly potent PI3K inhibitor bearing a difluoromethyl-pyrimidine moiety. *ACS Med Chem Lett.* 2019;10(10):1473–1479.
262. Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. *Cancer Res.* 2010;70(2):621–631.
263. Voss MH, Gordon MS, Mita M, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. *Br J Cancer.* 2020;123(11):1590–1598.
264. Burris 3rd HA, Kurkjian CD, Hart L, et al. TAK-228 (formerly MLN₀₁₂₈), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. *Cancer Chemother Pharmacol.* 2017;80(2):261–273.
265. Vuylsteke P, Huizing M, Petrakova K, et al. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase[PI3K]inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. *Ann Oncol.* 2016;27(11):2059–2066.
266. Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol.* 2016;17(6):811–821.
267. Powles T, Lackner MR, Oudard S, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. *J Clin Oncol.* 2016;34(14):1660–1668.
268. Lukey PT, Harrison SA, Yang S, et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. *Eur Respir J.* 2019;53(3):1801992.
269. Munster P, Aggarwal R, Hong D, et al. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. *Clin Cancer Res.* 2016;22(8):1932–1939.
270. Kim MN, Lee SM, Kim JS, Hwang SG. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. *Cancer Chemother Pharmacol.* 2019;84(4):809–817.
271. Brown JR, Hamadani M, Hayslip J, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. *Lancet Haematol.* 2018;5(4):e170–e180.
272. Mannick JB, Teo G, Bernardo P, et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. *Lancet Healthy Longev.* 2021;2(5):e250–e262.
273. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells *in vitro* and *in vivo*. *Clin Cancer Res.* 2011;17(22):7116–7126.
274. Sweeney CJ, Percent IJ, Babu S, et al. Phase 1b/2 Study of enzalutamide with samotolisib (LY3023414) or placebo in patients with metastatic castration-resistant prostate cancer. *Clin Cancer Res.* 2022;28(11):2237–2247.
275. Rubinstein MM, Hyman DM, Caird I, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. *Cancer.* 2020;126(6):1274–1282.
276. Hu X, Xia M, Wang J, et al. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. *Biomed Pharmacother.* 2020;129:110397.
277. del Campo JM, Birrer M, Davis C, et al. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. *Gynecol Oncol.* 2016;142(1):62–69.
278. Zhou C, Li X, He A, et al. Development of a UPLC-MS/MS method for the quantification of VS-5584 and its application in pharmacokinetic studies in rats. *J Anal Methods Chem.* 2020;2020:8811522.
279. Chen Y, Tsai HW, Tsai YH, Tseng SH. VS-5584, a PI3K/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas *in vitro* and *in vivo*. *J Pediatr Surg.* 2021;56(8):1441–1448.
280. Wen PY, Cloughesy TF, Olivero AG, et al. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. *Clin Cancer Res.* 2020;26(8):1820–1828.
281. Zhang J, Han W, Xie C, et al. Autophagy inhibitors alleviate Japanese encephalitis virus-induced cerebral inflammation in mice. *Arch Virol.* 2022;167(3):849–859.
282. Carter AN, Born HA, Levine AT, et al. Wortmannin attenuates seizure-induced hyperactive PI3K/akt/mTOR signaling, impaired memory, and spine dysmorphology in rats. *eNeuro.* 2017;4(3). ENEURO.0354-16.2017.
283. Dalal M, Jacobs-El N, Nicholson B, et al. Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol.* 2013;251(12):2705–2709.
284. La Manna F, De Menna M, Patel N, et al. Dual-mTOR inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. *Front Oncol.* 2020;10:1012.
285. Miodownik C, Lerner V, Kudkaeva N, et al. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. *Clin Neuropharmacol.* 2019;42(4):117–122.

286. Wightman EL, Haskell CF, Forster JS, Veasey RC, Kennedy DO. Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. *Hum Psychopharmacol.* 2012;27(2):177–186.
287. Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. *Hum Reprod.* 2013;28(6):1552–1568.
288. Bent S, Lawton B, Warren T, et al. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. *Mol Autism.* 2018;9:35.
289. Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. *Cancer Prev Res.* 2010;3(8):1015–1025.
290. Mahesh R, Jung HW, Kim GW, Kim YS, Park YK. Cryptotanshinone from *Salviae miltiorrhizae radix* inhibits sodium-nitroprusside-induced apoptosis in neuro-2a cells. *Phytother Res.* 2012;26(8):1211–1219.
291. D'Anna R, Cannata ML, Atteritano M, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. *Meno-pause.* 2007;14(4):648–655.
292. Shati AA. Salidroside ameliorates diabetic nephropathy in rats by activating renal AMPK/SIRT1 signaling pathway. *J Food Biochem.* 2020;44(4):e13158.
293. Zhu Z, Li J, Zhang X. Salidroside protects against ox-LDL-induced endothelial injury by enhancing autophagy mediated by SIRT1-FoxO1 pathway. *BMC Compl Alternative Med.* 2019;19(1):111.
294. Feng T, Cao W, Shen W, et al. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. *Oncotarget.* 2017;8(1):329–344.
295. Alam W, Rocca C, Khan H, et al. Current status and future perspectives on therapeutic potential of apigenin: focus on metabolic-syndrome-dependent organ dysfunction. *Antioxidants (Basel).* 2021;10(10):1643.
296. Sun Z, Yan B, Yu WY, et al. Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. *Exp Ther Med.* 2016;12(3):1879–1884.
297. Li GF, Qin YH, Du PQ. Andrographolide inhibits the migration, invasion and matrix metalloproteinase expression of rheumatoid arthritis fibroblast-like synoviocytes via inhibition of HIF-1 α signaling. *Life Sci.* 2015;136:67–72.
298. Zhang H, Li S, Si Y, Xu H. Andrographolide and its derivatives: current achievements and future perspectives. *Eur J Med Chem.* 2021;224:113710.